Skip to content

Educational reference only. Not medical advice. Nothing on this site is for sale.

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

Peptide CompendiumLanguageSign in

Stack

Melanotan II + PT-141

Two closely related melanocortin peptides. PT-141 (bremelanotide) was developed from Melanotan II.

What is in it

Sexual health & melanocortinEarly human dataFlashcard

Melanotan II

MT-II · MT2

Melanotan II is a lab-made peptide that copies a skin-darkening hormone (α-MSH).

Sexual health & melanocortinFDA-approvedFlashcard

PT-141 (bremelanotide)

bremelanotide · Vyleesi

Bremelanotide, often called PT-141, is a lab-made peptide that acts on melanocortin receptors in the brain.

Is there evidence for the combination?

We found no study of the two used together. Both act on the same receptors, so their side effects (nausea, flushing, blood-pressure rises, skin darkening) could overlap.

Each ingredient at a glance

Ingredient	Evidence	US FDA status	Sports (WADA)
Melanotan II	Early human data	Not FDA-approved for any use; FDA warned a seller in 2007 for marketing it as an unapproved, misbranded drug.	Not named on the 2026 List. Likely captured by S0 (non-approved substances,…
PT-141 (bremelanotide)	FDA-approved	FDA-approved as Vyleesi (June 21, 2019) for acquired, generalized HSDD in premenopausal women.	Not named on the 2026 List; as an approved drug it is not an S0 substance.

Mixing adds unknowns. A blend carries the risks of every ingredient, and the interactions are untested. Vial contents and ratios are set by sellers and are not standardized. See each ingredient page for safety and legal details.